the electrical activity from bundles of pelvic fibres, we found that the P2X agonists (ATP and a,b-meATP) applied intravesically could rapidly activate pelvic afferents and potentiate their response to bladder distension in P2X 3 wildtype but not in P2X 3 knockout mice. The P2X antagonist pyridoxal phosphate 6-azophenyl-2',4'-disulfonic acid (PPADS), on the other hand, markedly reduced the mechanosensitive responses in the pelvic afferents of P2X 3 wild-type mice.
The urinary bladder receives a dual afferent innervation that travels via the hypogastric and the lumbar splanchnic nerves and also via the pelvic nerves (Cervero, 1994) . Investigations in humans indicated that all sensations from the bladder including pain and innocuous filling are signalled mainly by the pelvic afferents (Kuru, 1965) . Neurophysiological studies have shown that the bladder afferents are small myelinated A d and unmyelinated C fibres and fall into three categories depending on their stimulus-response characteristics. The first group represent the largest population of afferents and respond to bladder distension with a low threshold (LT fibres). The second group respond to distension of the bladder with a high threshold (HT fibres). The third group are normally insensitive to bladder distension but can be sensitised during inflammation to become mechanosensitive ('silent' fibres). It has been speculated that the activation of LT fibres triggers micturition whilst the activation of HT and 'silent' fibres initiates painful sensation.
In the present report, we attempt to determine which of the above groups of fibres is involved in the purinergic mechanism of sensory transduction. The question is addressed by analysing the effects of the P2X agonist a,bmeATP and the P2X antagonist TNP-ATP on single unit pelvic afferent activity recorded from P2X 3 wild-type mice.
METHODS

Animals
Four-to six-month-old P2X 3 wild-type mice (6 male, 8 female, 27.6 ± 1.3 g) were used in this study. The breeding of these animals has been described previously (Cockayne et al. 2000) . Maintenance and killing of the animals used in this study followed principles of good laboratory animal care and experimentation in compliance with UK national laws and regulations. The mice were killed humanely by exposure to a rising concentration of CO 2 and cervical dislocation.
Preparation and nerve recording
The whole urinary tract attached to the surrounding tissues was dissected from the animal and placed in a recording chamber. The tissue was continuously superfused with oxygenated (95 % O 2 -5 % CO 2 ) Krebs solution (contents, mM: NaCl 120; KCl 5.9; NaH 2 PO 4 1.2; MgSO 4 1.2; NaHCO 3 15.4; CaCl 2 2.5; glucose 11.5).
In five experiments using the male mice, a 25G needle was inserted into the bladder and was connected to a three-way Omnifit (Cambridge, UK) to enable infusion/withdrawal of fluid and recording of intravesical pressure. The outlets (the ureters and the urethra) of the bladder were all tied. In the experiments using female mice, a catheter was inserted into the bladder through a small cut on the fundus of the bladder. Another catheter was inserted into the bladder through the urethra. The catheters were secured in place by ligatures with 7-0 sutures. The pelvic nerves were carefully dissected into several fine branches and were recorded using a suction electrode. Electrical activity was picked up by a Neurolog headstage (NL100, Digitimer Ltd, UK), amplified (NL104), filtered (NL125, band pass 300-4000 Hz) and captured by a computer via a power 1401 interface and Spike 2 software (version 3.02, CED, UK).
Experimental protocols
After approximately a 60 min period of stabilisation, the bladder was distended with Krebs solution (0.1 or 0.2 ml min _1 ) to an intravesical pressure of 40 mmHg or above, followed immediately by evacuation of the fluid. This was repeated several times at intervals of 10-15 min to assess the viability of the preparation and the reproducibility of pressure and neuronal responses to distension. To test the effect of a,b-meATP on the bladder afferents, 0.1 ml test solution (0-1 mM a,b-meATP, lithium salt, Sigma, USA) was injected as a bolus into the bladder. The effects of a,b-meATP on the mechanosensitive property of the bladder afferents were studied by comparing the afferent responses to bladder distensions following pre-exposure to vehicle (0.1 ml) or a,b-meATP (1 mM, 0.1 ml) or by comparing the afferent responses to bladder distensions with vehicle or 0.1 mM a,bmeATP. To determine whether endogenous ATP contributes to mechano-sensory transduction in bladder afferents, the bladder was distended with vehicle or 0.03 mM TNP-ATP.
Data analysis
Multifibre afferent nerve activity was quantified by spike counting using a spike processor (Digitimer D130). Some of the multifibre recordings contained only a few units with sufficiently different spikes to allow off-line single unit discrimination using the Spike 2 software. Baseline afferent activity was obtained by averaging the discharge rate in the 1 min period prior to agonist treatment or bladder distension. The response to a treatment was quantified by averaging the firing rate in every consecutive 10 s from the onset of that treatment. Single units (or nerve branches) were considered as responding to a challenge if the change in discharge rate was greater than 20 %. 'Silent' units were considered to respond to a challenge even if only one spike was discharged following that treatment. Where appropriate, data are expressed as means ± S.E.M. Responses were compared by Student's paired t test. Statistical significance was assured at P < 0.05.
RESULTS
Multifibre bladder afferent activity
A typical multifibre recording taken from the pelvic nerve demonstrates the activity of mouse bladder afferents ( Fig. 1) . At rest, with the bladder empty, there was little background activity (< 10 imp s _1 ). However, as the bladder pressure increased to a threshold level (8.9 ± 1.1 mmHg, range 0.5-11.5 mmHg, n=10), the afferents started to discharge and the firing rate increased progressively as the pressure rose. The nerve responses to bladder distension were fairly consistent for repeated trials (Fig. 1) .
Intravesical administration of a,b-meATP (1 mM, 0.1 ml) reliably evoked a marked elevation in multifibre afferent discharge and a modest increase in bladder pressure in all cases (n=10, Fig. 2A ). However, the magnitude of the afferent response showed great variability. This may be because of the variable number of active fibres in each multifibre recording or a variable percentage of fibres that express P2X receptors. Consequently, to plot the concentration-response bar graph (Fig. 2B ), the afferent responses to different concentrations of the agonist were expressed as a percentage of the response to the highest concentration used (1 mM, 0.1 ml) in each experiment. The plot shows that the afferent responses to a,b-meATP were concentration dependent. Figure 3 demonstrates the effects of the P2X agonist a,bmeATP and the antagonist TNP-ATP on the multifibre afferent response to bladder distensions. In six multifibre preparations tested, a,b-meATP greatly increased the magnitude of the afferent response to bladder distension in all cases without apparent effect on the threshold of the response. In control distensions with vehicle, the peak firing rate averaged 83.7 ± 17.4 imp s _1 , and afferent discharge reached a peak rate of 134.3 ± 26.6 imp s _1 (P < 0.01 vs. control) in distensions with a,b-meATP (0.1 mM). In contrast, TNP-ATP significantly reduced the afferent response to bladder distension, again with no apparent effect on the threshold. The firing rate reached a peak of 85.8 ± 10.6 and 63.2 ± 10.3 imp s _1 (P < 0.01) in control and in the presence of TNP-ATP, respectively. It is noteworthy that the afferent discharges that occurred at lower bladder pressure (< 15 mmHg) were not affected by the antagonist, but the discharges at higher bladder pressure (>15 mmHg), were attenuated (see Fig. 3 ).
Single fibre afferent activity
The pelvic nerves were dissected further such that each branch only contained a few fibres. In the afferent recording illustrated in Figure 4 , six individual units were A, afferent discharges evoked by bladder distension. The rates of 3 apparently different units (labelled U1, U2 and U3) are displayed. Note they differ considerably with respect to threshold and discharge rate and can be classified as low threshold (LT, U1) and high threshold (HT, U2 and U3) fibres. B, afferent discharges induced by intravesical application of a,b-meATP (1 mM, 0.1 ml) in the same nerve preparation as in A. Bin = 10 s for A and B. C, superimposed spikes for U1, U2 and U3.
induced to discharge by bladder distension. These units displayed sufficiently different spike amplitude and shape to allow accurate spike discrimination, as exemplified by the three units illustrated (Fig. 4C ). Each had a distinct threshold and markedly different peak firing rate at a given bladder pressure. All three units could be activated by an intravesical application of a,b-meATP (1 mM, 0.1 ml, Fig. 4B ). In 19 fibre preparations from 14 mice, a total of 149 individual units were analysed. The majority of these fibres were silent at rest (with the bladder empty) with only 11 (6.5 %) fibres having some ongoing activity (1-5 imp (10 s) _1 ). Ninety-six units started to discharge at a bladder pressure of < 15 mmHg (mean 7.1 ± 0.4 mmHg) and their activity increased with further increments in bladder pressure (see Fig. 4A , unit 1). These units were designated as low threshold (LT) fibres. Forty-two units were induced to fire at a pressure greater than 15 mmHg (mean 27.3 ± 1.7 mmHg) and were designated as high threshold (HT) fibres (see Fig. 4A , units 2 and 3). Eleven units did not respond to bladder distensions even at pressures of 50 mmHg, but they became sensitive to bladder distensions in the presence of a,b-meATP (e.g. unit 3 in Fig. 5 ). These units were defined as 'silent' units.
Twenty-one of 32 (65.6 %) LT fibres could be induced to discharge by an intravesical injection of a,b-meATP (1 mM, 0.1 ml) after a latency of 1-75 s (see unit 1 Fig. 4B ). The maximal response (mean 38.2 ± 11.9 imp (10 s) _1 ) was observed 30-100 s after application of the agonist. Fourteen of 25 (56 %) HT fibres could also be activated after a latency of 10-175 s and reached peak activity (19.7 ± 4.8 imp (10 s) _1 ) 50-180 s after application of a,b-meATP (see units 2 and 3 in Fig. 4B ).
The effects of a,b-meATP on the mechano-sensory properties of single bladder afferents were studied by comparing their response to bladder distension after preexposure to vehicle (Krebs solution) or 1 mM a,b-meATP (0.1 ml). A large proportion (46/77, 59.7 %) of LT fibres showed a greater response to bladder distension in the presence of a,b-meATP (e.g. unit 1 in Figs 5 and 8 ). On average, the peak firing rate of these 46 units during ). Bin = 10 s for A and B. C, the superimposed action potential for the unit. distension in the presence of a,b-meATP (e.g. unit 2 in Figs 5 and 8) . The threshold for the response to bladder distension was lowered from an average of 25.6 ± 2.6 to 15.1 ± 1.0 mmHg (P < 0.01), whereas the mean peak firing rate was increased from 57.8 ± 13.9 (range 1-160) imp (10 s) _1 in control to 123.8 ± 29.7 (range 1-284) imp (10 s) _1 (P < 0.01) after the agonist treatment. Furthermore, an additional 11 units, which did not respond to bladder distension in the control situation ('silent' fibres), became sensitive to bladder distension after pre-exposure to a,b-meATP (e.g. unit 3 in Fig. 5 ).
The effects of the P2X antagonist TNP-ATP on the mechano-sensory properties of bladder afferents were analysed in 51 LT and 19 HT fibres, by comparing their response to bladder distensions with vehicle or 0.03 mM TNP-ATP. The antagonist did not affect the threshold for the response of LT fibres to bladder distension (7.05 ± 0.48 vs.7.22 ± 0.55 mmHg, P > 0.05). However, it caused a moderate reduction in the peak response (from 56.3 ± 9.8 to 41.1 ± 9.7 imp (10 s) _1 , P < 0.05) of 22 (43.1 %) LT fibres (Figs 6 and 8C) . The responses of the other 29 (56.9 %) units were unaffected by the antagonist. On the other hand, the antagonist resulted in a markedly elevated threshold (from 25.1 ± 1.9 to 36.4 ± 2.1 mmHg, P < 0.05) and a significantly reduced peak firing rate (from 48.6 ± 13.5 to 19.8 ± 7.2 imp (10 s) _1 , P < 0.01) in the majority (13/16, 81.3 %) of HT fibres (Fig. 7, Fig. 8D ). The effects of TNP-ATP on the responses of LT and HT fibres were reversible after washout of the antagonist.
DISCUSSION
The present study has employed an in vitro mouse bladder-pelvic nerve preparation to investigate the effects of the P2X agonist a,b-meATP and the antagonist TNP- ATP on the activity and mechano-sensory properties of bladder afferent fibres. Using this preparation, it was possible to record reproducible afferent responses to bladder distensions over several hours (Fig. 1) , thus permitting quantitative analysis of the possible involvement of purinergic mechanisms in sensory transduction in the fibres with afferent endings in the bladder. Our results revealed that intravesically applied a,b-meATP could activate, in a concentration-dependant manner, pelvic afferents and potentiate their response to bladder distension, whereas TNP-ATP reduced responses to bladder distension in most cases (Figs 2 and 3) .
Types of bladder afferents
Mechano-sensitive afferent fibres innervating the bladder were first described by Evans (1936) in cats and Talaat (1937) in dogs. They recorded the electrical activity of bundles of fibres in hypogastric and pelvic nerves and concluded that they were sensitive to stretch of the bladder wall. In addition, Talaat (1937) also reported that some of the afferent fibres in the hypogastric nerve had high thresholds for response to bladder distension and therefore their function could be related to painful sensations. Iggo (1955) postulated that the pelvic afferent fibres sensitive to bladder distension were tension receptors located in series with the smooth muscle fibres. These afferents have been shown to have a low threshold to passive bladder distension and also to respond to normal bladder contractions associated with voiding (Bahns et al. 1986 ).
The presence of populations of low (LT) and high threshold (HT) bladder afferents in the pelvic nerve has been well documented in in vivo studies in the cat (Häbler et al. 1990 (Häbler et al. , 1993 and the rat (Sengupta & Gebhart, 1994) . In addition, a third population of afferents that were normally insensitive to even noxious bladder distension were identified in inflamed bladder in the cat (Häbler et al. 1990) . These were called 'silent receptors' or 'chemosensitive fibres'. As far as we know, the present study is the first attempt to analyse the single unit activity of pelvic afferents in the mouse. In agreement with previous in vivo studies in rats and in cats, bladder afferents were identified in this species with similar stimulus-response characteristics using an in vitro mouse bladder/pelvic nerve preparation (Figs 4 and 5) . The results demonstrate the existence of LT, HT and 'silent' (chemosensitive) bladder afferents in the pelvic nerve in this species.
Activation and sensitisation of bladder afferent by a,b-meATP
Although a considerable amount is known about the stimulus-response properties of the afferents innervating the urinary bladder, very little is known about how mechanical stretch to the bladder wall is actually transduced into a receptor potential in afferent terminals. Studies since the 1980s have demonstrated that many substances, especially irritant chemicals (such as mustard oil and turpentine oil) (Häbler et al. 1988 (Häbler et al. , 1990 and inflammatory mediators (such as bradykinin, serotonin, substance P, histamine, prostaglandin E2 and K + ) (Sengupta & Gebhart, 1994) are able to activate these afferents and, more importantly, modulate their mechanosensory properties.
In the present study, we found that a large proportion of LT (21/32, 65.6 %) and HT (14/25, 56 %) fibres could be activated by intravesical application of the selective P2X agonist a,b-meATP (0.1 ml, 1 mM). In addition, 11 'silent' fibres could also be induced to discharge by the agonist. The afferent responses following application of the agonist were obscured by the increase in bladder pressure that resulted from detrusor muscle contraction, possibly due to concomitant activation of P2X 1 receptors. However, there was clear evidence for a direct action of the agonist on the afferents, since the increase in pressure was moderate and the afferents discharged more vigorously than could be attributed to the increase in pressure alone (compare afferent activity in Fig. 4A and B) .
In addition to activation of the afferents, another important aspect of the effects of intravesically applied a,b-meATP was the potentiation of afferent responses to bladder distensions and the sensitisation of 'silent' fibres. In this respect, it is interesting to note that the vast majority (21/22, 99.5 %) of HT fibres exhibited greater sensitivity (lowered threshold and increased peak activity) to bladder distension in the presence of a,b-meATP, whereas a smaller proportion (46/77, 59.7 %) of LT fibres were sensitised by the agonist (increased peak activity) and no change in threshold was observed.
The solution of a,b-meATP applied intravesically contained maximally 3 mM lithium (Li + ), but the changes in afferent activity following application of a,b-meATP were unlikely to be mediated by Li + through epithelial sodium channels. Rather, the changes appeared to be mediated by P2X receptors. We have recently compared multifibre afferent activity following intravesical injection of 0.1 ml vehicle with 3 mM lithium and 0.1 ml solution containing 1 mM a,b-meATP. Whilst a,b-meATP resulted in marked activation of the afferents, there was little change in afferent activity following 3 mM Li + . Furthermore, we have shown in an earlier report that TNP-ATP could effectively antagonise the excitatory action of a,b-meATP on the bladder afferents (Vlaskovska et al. 2001 ).
P2X receptors have been shown to exist in the urinary bladder (see Burnstock, 2001 ). P2X 1 receptors were found on detrusor muscles (Ferguson, 1999; Lee et al. 2000) whereas P2X 3 receptors were localised in the urothelium (Ferguson, 1999) . We have previously demonstrated P2X 3 immunostaining on afferent fibres (Cockayne et al. 2000; Vlaskovska et al. 2001) , whereas Elneil et al. (2001) reported that P2X 3 immunostaining in the urothelium (of rat and human bladder) was not associated with CGRPcontaining sensory fibres. Thus, the effects of a,b-meATP on the bladder afferents might be mediated by the activation of P2X 3 (or P2X 2/3 ) receptors located on afferent terminals. Alternatively, the agonist might activate P2X 3 receptors on urothelial cells, which then release substances (including ATP) to stimulate the afferent terminal.
The afferent terminals are located mainly in the subepithelial layer, but some fibres penetrate into the basal layer of the urothelial cells and others terminate in between detrusor muscles. To stimulate the afferents directly, a,b-meATP needs to cross the urothelium and diffuse through to the terminals. We are not sure how readily a,b-meATP can do so. It appears that the agonist can penetrate the urothelium quite fast since the bladder contracted quickly following intravesical administration of the agonist (see Fig. 2 ), indicating activation of P2X 1 receptors on detrusor muscles. It is not clear whether different receptor mechanisms account for the activation and the sensitisation of bladder afferents. However, the afferent activity induced by intravesical application of a,b-meATP faded quickly despite continued exposure to the agonist (Figs 2 and 5) , implying an important role of the rapidly desensitising P2X 3 subtypes for the activation of the afferents. On the other hand, the agonist continued to sensitise the afferents after cessation of the ongoing activity (e.g. units 1-3 in Fig. 5 ). This might indicate an involvement of P2X 2/3 heteromultimers in the sensitisation of bladder afferents.
Modulation of bladder afferents by endogenous ATP
We applied TNP-ATP to block the action of endogenous ATP on bladder afferents. TNP-ATP has been shown to be a potent and selective antagonist of homomultimeric P2X 1 , P2X 3 and heteromultimeric P2X 2/3 receptors with an IC 50 of 1-6 nM (Virginio et al. 1998; Burgard et al. 2000) . The efficacy of TNP-ATP was reduced in whole tissue experiments (IC 50 30 mM, Lewis et al. 1998) , possibly due to its breakdown by nucleotidases. We have previously shown that TNP-ATP (30 mM) effectively blocked the excitatory action of a,b-meATP on bladder afferents (Vlaskovska et al. 2001) . In the present study, TNP-ATP resulted in a significant reduction in the multifibre afferent discharge at high (>15 mmHg) bladder pressure, indicating an involvement of endogenous ATP in the mechanosensory transduction. Single unit analysis demonstrated that whilst only 43.1 % of LT fibres were affected by TNP-ATP, the majority (81.3 %, 13/16) of HT fibres showed a raised threshold and reduced peak response to bladder distensions. This can probably be explained by the fact that bladder distension induced a pressure-dependent release of ATP (Vlaskovska et al. 2001 ).
In the human, a sensation of fullness occurs at an intravesical pressure of 5-15 mmHg. This is followed by an urge to void at an intravesical pressure of 20-25 mmHg. The first sign of discomfort occurs when intravesical pressure exceeds 25 mmHg and pain is perceived when micturition is prevented and bladder pressure exceeds 30 mmHg. Our findings with the P2X antagonist suggest that endogenously released ATP may be involved in innocuous as well as nociceptive sensory processing in the bladder.
Perspectives
The involvement of a purinergic mechanism in mechanosensory transduction in the urinary bladder is of considerable interest. Normal bladder function requires co-ordinated contraction and relaxation of detrusor and urethral sphincter muscles and this depends on sensory inputs from the bladder to control centres in the spinal cord, pons and forebrain. There is a high incidence of lower urinary tract symptoms (such as incontinence and pain) that may be associated with afferent nerve activity. Although direct evidence for an involvement of a purinergic sensory mechanism in pathological bladder is still lacking, in theory, increased release of ATP and/or increased expression of P2X 3 receptors meant increased afferent activity in LT fibres which may in turn lead to more frequent micturition and increased afferent activity in HT fibres which may cause bladder pain. Indeed, there is now good evidence that P2X 3 receptors may be upregulated in the state of inflammation (Hamilton et al. 1999 (Hamilton et al. , 2001 Zhang et al. 2001) and are essential for inflammatory pain (Souslova et al. 2000) . There is also evidence that inflamed cells release more ATP (Bodin & Burnstock, 1996) . Thus, in our opinion, it is likely that purinergic sensory signalling may be up-regulated and may contribute to the symptoms of bladder inflammation. Agents that reduce ATP release, or block P2X 3 (and/or P2X 2/3 ) receptors, may be potentially effective in relieving over-activity and pain of the bladder associated with inflammation.
